/div>

Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

A novel enzyme developed by research scientists at Promega Corporation will virtually eliminate confounding stutter artifacts in forensic DNA analysis. The reduced stutter polymerase dramatically sim

plifies mixed sample deconvolution and allows forensic analysts to generate accurate profiles of multiple contributors. This is the first enzyme to solve one of the biggest challenges in DNA forensics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920660502/en/

ucing confounding stutter artifacts. (Graphic: Business Wire)"/>

Promega Corporation unveils a novel enzyme that will dramatically simplify forensic DNA analysis by significantly reducing confounding stutter artifacts. (Graphic: Business Wire)

“By eliminating stutter artifacts, an analyst can more accurately identify low-level contributors and better determine the number of contributors in highly complex mixtures,” says Michael Coble, Executive Director of the Center for Human Identification at the University of North Texas Health Science Center.

Stutter has been a major pain point for the forensics community for decades. The naturally occurring errors may cause analysts and software to discard potentially useful pieces of data. Using the n

ew polymerase developed by Promega, analysts will no longer have to sort through small peaks to separate useful data from noise.

“Because they don’t have to worry about stutter peaks anymore, forensic DNA analysts will be able to get more valuable information out of each sample,” says Bob McLaren, Director of Research at Promega. “Hopefully, that will lead to solving more cases, and doing it all much faster.”

This innovation was first announced at the International Symposium on Human Identification. Promega has applied for a patent covering this novel enzyme for use in STR analysis.

Stutter in STR Analysis

Forensic DNA analysis is based on the amplification and detection of short tandem repeats (STRs). STRs are regions of DNA where short seq

uences are repeated multiple times in a row. When the sequence is being amplified using Taq polymerase, the enzyme has an occasional tendency to slip across the repeats, resulting in a new fragment that is one repeat shorter than the template. When the fragments are separated and detected by capillary electrophoresis, the data will show an extra peak that is one repeat shorter than the true peak.

This creates challenges when a sample contains DNA from multiple contributors. It can be extremely challenging to determine whether a peak represents stutter or an allele from a minor contributor. This is a longstanding pain point for forensic DNA analysts.

Reduced Stutter Polymerase

The novel enzyme announced by Promega is a genetically modified version of Taq polym

erase that includes features from T7 DNA Polymerase and additional mutations that allow it to more tightly bind to its template strand. The result is an enzyme that reduces stutter by an order of magnitude relative to current systems, rendering it undetectable behind instrument baseline noise.

Promega plans to integrate the new reduced stutter polymerase into future 8-color STR analysis kits. Promega is also the first manufacturer to launch 8-color STR chemistry, which enables analysts to generate more data from complex or degraded samples. When analyzed on the Spectrum CE System, the combined technologies will empower forensic laboratories to generate the most reliable and high-quality data for forensic casework.

Promega has been developing and manufacturing products for DNA-based human identification for more than 35 years.

Register to receive updates on the availability of reduced stutter polymerase here.

Learn more about Promega reagents and instruments supporting DNA forensics here.

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240920660502/en/